Endosulfatases: Promising Therapeutic Targets in Cancer and Inflammatory Diseases

Endosulfatases, specifically HSulf1 and HSulf2, are key enzymes that regulate heparan sulfate (HS) chain structure by hydrolyzing 6-O-sulfate groups.This modulation of HS is crucial, as HS interacts with various proteins to influence critical biological processes.Dysregulation of HS sulfation is implicated in diseases like cancer and inflammation, highlighting endosulfatases as potential therapeutic targets.These enzymes function extracellularly at neutral pH, distinguishing them from other sulfatases and offering a pathway for selective therapeutic intervention.Current inhibition strategies focus on substrate mimetics, particularly sulfamate-containing compounds, which act as irreversible inhibitors.These inhibitors, however, present challenges for structural studies due to their mechanism of action.Emerging strategies explore inhibitors with functional groups for bioconjugation, leveraging the formylglycine group in the enzyme's active site.Chemical, enzymatic, and genetic methods can introduce carbonyl groups into proteins, enabling the attachment of therapeutic agents.Reactions like oxime/hydrazone formation and cycloadditions offer versatile routes for inhibitor conjugation.The development of specific endosulfatase inhibitors holds promise for treating diseases with aberrant HS sulfation.Precisely modulating endosulfatase activity could disrupt pathological HS interactions, offering new therapeutic avenues.Future research should aim to enhance inhibitor potency and selectivity and explore targeted drug delivery to the extracellular matrix.